Laprophan invests 374 million dirhams in injectable drugs plant
By the AFREEQUE newsroom, based on La Vie éco
Illustrative image · Pilan Filmes · Pexels · Licence PexelsMoroccan pharmaceutical group Laprophan, through its Amanys Pharma subsidiary, is preparing a sterile injectable drugs plant in Aïn El Aouda, near Rabat, for 374 million dirhams, with operations due to begin in 2027. The facility, with a capacity of 30 million units a year over 18,000 sq m, is intended to meet European standards, according to La Vie éco.
The new sterile injectable drugs manufacturing unit of Amanys Pharma, a subsidiary of Moroccan pharmaceutical group Laprophan, is due to enter service in 2027 in Aïn El Aouda, in the Rabat region. Built on 18,000 sq m within a 62,000 sq m industrial complex, it will be able to produce 30 million consumer sales units per year, according to La Vie éco.
The facility will manufacture injectable drugs packaged in bottles and flexible bags and will have storage capacity for 7,000 pallets. Its design, carried out in accordance with European good manufacturing practices, took nearly four years. Mohammed Squalli Houssaini, deputy managing director and responsible pharmacist at Amanys Pharma, said the site meets European and American requirements applicable to this type of production, with a closed system intended to limit contamination risks, according to La Vie éco.
The facilities are now industrially ready and are expected to enable Laprophan to meet demand in the Moroccan market before gradually developing exports to African and European markets, according to La Vie éco.
